Top 5 Organ on Chip Companies
.png)
Published: February 2025
The potential of microfluidic organ-on-chips in precisely mimicking the human body’s microenvironment has completely reformed the drug discovery process, offering an effective ethical alternative to animal-based testing models. We analyzed the key companies that are engaged in providing organ-on-chip technologies / models and chips / plates. In this article, discover the 5 leading organ on chip companies and the organ-on-chip products they offer.
Organ-on-chips are in vitro microfluidic products, housing 3D cultured living cells that mimic the human physiology on a chip, providing in depth descriptions of the cell microenvironment and disease pathophysiology. In the late 1990’s, in the pursuit of identifying efficient, quick and cost-effective drug discovery approaches, Michael Shuler, a chemical engineer at Cornell University, first developed a living human animal-on-a-chip. Later, the Defence Advanced Research Projects Agency (DARPA), National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) provided additional support grant of USD 37 million to Ingber and his team for the development of 15 organ-on-chip models, featuring the lung, intestine, kidney and bone marrow. Since then, the organ-on-chip domain has witnessed significant advancements, revolutionizing drug discovery and testing while eliminating the need of animal-based models.
Organ-on-chips are developed using microfabrication techniques, by carving microfluidic chambers and channels on a polymer-based chip (usually PDMS (polydimethylsiloxane)). These chambers are then cultured with live cells / tissues of interest, that are continually perfused with cell culture media through the connecting channels. These chips are primarily being developed in two formats: organ / multi-organ specific chips and disease-based chips. Organ / multi-organ specific chips imitate the physiology of a particular organ / multi-organs on a chip, such as the heart, liver, lungs, and others or their combinations. Whereas, the disease based chips aid in studying the key aspects of organ / tumor microenvironment in diseased state, for identifying the drug response across various therapeutic areas.
Given the various advantages of using organ-on-chip for drug discovery, research and ADME toxicology testing studies such as accurate recreation of human biology, animal-free testing and potential in precision medicine by using patient’s samples for testing, organ-on-chips are witnessing widespread adoption in the healthcare domain. Further, considering the expanded research and development efforts of stakeholders in this domain, the organ-on-chip market is poised to grow at a significant growth rate.
Roots Analysis has conducted an exhaustive study on Organ-on-chip Market featuring the current market landscape and future opportunity for the organ-on-chip technologies / models and chips / plates over a span of 10 years.
Table of Contents
The top 5 organ-on-chip companies are listed below (in alphabetical order):
Table 1: List of Top 5 Organ-on-chip Companies
| S.No. | Organ-on-chip Companies | Year of Establishment | Location of Headquarters (Country) | Location of Headquarters (Region) |
| 1 | CN BIO | 2008 | Cambridge, UK | Europe |
| 2 | Dynamic42 | 2018 | Thuringia, Germany | Europe |
| 3 | Emulate | 2014 | Massachusetts, US | North America |
| 4 | InSphero | 2009 | Zürich, Switzerland | Europe |
| 5 | SynVivo | 2015 | Alabama, US | North America |
Interested in exploring the portfolio and activity of other organ-on-chip companies?
Discover the Details on 5 Organ-on-chip Companies
This article highlights the top 5 players to watch out for in this industry. These companies were chosen based on their product offerings (companies providing both organ-on-chip technologies / models as well as chips / plates). It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. CN BIO, Working Towards its Goal for Expansion in the Asia-Pacific Markets
 |
CN Bio is a UK based company specializing in recreating 3D human organs in the laboratory to enhance the overall understanding of human physiology, drug efficacy and disease response. The company envisions a quicker and cost-effective drug discovery process while minimizing reliance on animal testing. Through its organ-on-chip technologies, the company enhances the quality of three-dimensional disease models or tissue models, allowing for more precise observations of drug actions and metabolic pathways.
CN BIO offers the following organ-on-chip technologies / models:
- PhysioMimix® OOC Microphysiological Systems
- Liver-on-a-chip model
- Lung-on-a-chip model
- Gut/Liver-on-a-chip models
Organ-on-chips / Plates Offered:
- MPS-T12 (Barrier Plate)
- MPS-TL6 (Dual-organ Plate)
- MPS-LC12 (Liver-12 Plate)
- MPS-LC48 (Liver-48 Plate)
Type of Model Offered:
- Organ / Multi-organ based
- Disease / Pathology based
Compatible Cells / Tissues / Organs / Organ Barriers:
- Lung
- Liver
- Other Cells / Tissues / Organs / Organ Barriers
Application Area:
- Drug Discovery / Toxicology Testing
- Cancer Research
Recent Developments:
In January 2025, the company signed a distribution agreement with Japan based Primetech for the market expansion of its PhysioMimix® OOC Systems in the region. This came after their distribution agreement with Australia based AXT Pty Ltd. in May 2019.
In June 2024, the company appointed Lydia Seymour as Vice President of People and Culture.
In April 2024, the company announced its selection to participate in Phase I of the SensOoChip challenge by NC3Rs. The initiative aims to enhance the utility and reproducibility of connected organ-on-chip models by incorporating real-time multiparametric monitoring in order to reduce reliance on animal-based testing.
Further, In April 2024, raised USD 21 million in a Series B funding round led by Bayland Capital for scaling up its business and expanding its organ-on-chip product portfolio.
To know more about CN BIO and other organ on chip companies, access our full report.
2. Dynamic42, Developing and Marketing 3D Microfluidic in vitro Cell Culture Platforms for Industry and Academic Institutes
 |
Dynamic42, a Germany-based, spin-off company from the University Hospital Jena, develops and commercializes advanced 3D organ-on-chip models for research and development, and pharmaceutical testing. The company offers a range of products, including microfluidic chips, liver sinusoid, alveolus and intestine models. The company’s organ-on-chip platform enables absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies, as well as toxicity screenings on intricate micro physiological human organs models in preclinical stages. Leveraging its platforms, the firm supports commercial manufacturers, researchers and developers in planning and conducting preclinical studies.
Dynamic42 offers the following Organ-on-chip technologies / models:
- DynamicOrgan System
- Liver-on-Chip
- Intestine-on-Chip
- Lung-on-Chip
- Vasculature-on-Chip
Organ-on-chip / Plate Offered:
- Dynamic42 biochips
Type of Model Offered:
- Organ / Multi-organ based
- Disease / Pathology based
Compatible Cells / Tissues / Organs / Organ Barriers:
- Lung
- Liver
- Other Cells / Tissues / Organs / Organ Barriers
Application Area:
- Drug Discovery / Toxicology Testing
Recent Developments:
In July 2024, the company participated in EUROoCS Annual Meeting, held in Milan, Italy.
In June 2024, the company launched an open platform for organ model development. The DynamicOrgan System is an open platform which requires no capex spending, and it seamlessly integrates into any standard cell culture environment, allowing the researchers to create realistic human organ models to study various bioprocesses.
In January 2024, the company entered into a strategic partnership with Biopredic to jointly advance the development of in vitro assay systems by integrating Biopredic cells with the former company’s organ models.
To know more about Dynamic42 and other organ on chip companies, access our full report.
3. Emulate, Investing its Efforts to Develop Next Generation Organ-on-a-chip Products
 |
Emulate is a US-based biotechnology firm involved in developing advanced in vitro models for emulation of human biology by combining human cell sourcing, an organ-specific microenvironment, and tissue-relevant mechanical forces. Further, the company offers a range of organ-on-chip products to evaluate the efficacy of clinical drug candidates and drug related injuries such as drug-induced liver injury. In addition, the company holds exclusive global rights and licenses to the organ-on-chip technology developed at Harvard University. The company claims to work with various clinical partners to produce personalized chips that simulate stem cells.
Furthermore, through its services and product offerings, the firm expects to achieve three key goals, namely developing a new framework for understanding human biology; using its own system and data to improve human health; and fostering a new age of personalized medicine.
Emulate offers the following Organ-on-chip technologies / models:
Human Emulation System
- Brain-Chip
- Lung-Chip
- Kidney-Chip
- Liver-Chip
- Colon Intestine-Chip
- Duodenum Intestine-Chip
Organ-on-chips / Plates Offered:
- Chip-S1 (Stretchable Chip)
- Chip-A1 (Accessible Chip)
Type of Model Offered:
- Organ / Multi-organ based
- Disease / Pathology based
Compatible Cells / Tissues / Organs / Organ Barriers:
- Lung
- Liver
- Brain
- Other Cells / Tissues / Organs / Organ Barriers
Application Area:
- Drug Discovery / Toxicology Testing
- Stem Cell Research
- Cancer Research
Recent Developments:
In September 2024, the company launched Chip-R1™ Rigid Chip for ADME toxicology testing, offering lower drug absorption.
In December 2023, Emulate received the 2023 Frost and Sullivan’s Technology Innovation Leadership Award for successful development of organ-on-a-chip technology, that supports the development of human-relevant models and reduce animal dependency for testing.
In June 2023, the company announced the launch of Chip-A1 Accessible Chip, which offers an improved 3D in vitro modeling for applications in cancer research.
To know more about Emulate and other organ on chip companies, access our full report.
4. InSphero, Collaborating on Several Projects Focused on Organ on Chip Technology for Advancements in the Field
 |
InSphero is a Switzerland based spinoff company from Swiss Federal Institute of Technology which aims to develop alternatives to animal testing for drug discovery. In 2010, the company introduced its first innovation, the Akura PLUS Hanging Drop System, which allowed the formation of spheroids from cells that could not aggregate on ultra-low attachment surfaces. Building on this success, the company developed its first 3D human derived microtissue in 2012 as a part of its 3D InSight platform. Later in 2014, the company developed its 3D InSight portfolio by creating an islet microtissue model, marking a new breakthrough in drug research for Type 1 and Type 2 Diabetes. Notably, in 2023, the company expanded its distribution networks across Europe, the US and Asia in order to cater to the growing global demands of 3D tissue models.
InSphero offers the following Organ-on-chip technology / model:
- Akura™ Organ-on-Chip Technology
Organ-on-chips / Plates Offered:
- Akura™ Flow 384 Multi-Organ Platform
- Akura™ Immune Flow Organ-on-Chip Platform
- Akura™ Flow Organ-on-Chip Platform
- Akura™ Twin Microplate
Type of Model Offered:
- Organ / Multi-organ based
- Disease / Pathology based
Compatible Cells / Tissues / Organs / Organ Barriers:
- Lung
- Other Cells / Tissues / Organs / Organ Barriers
- Multi-Organs
Application Area:
- Drug Discovery / Toxicology Testing
- Cancer Research
Recent Developments:
In November 2024, InSphero entered into a distribution agreement with South Korea based Chayon for distribution of Akura™ Plate Technology and Akura™ Organ-on-Chip Platforms to researchers in the region.
In May 2024, the company entered into a commercialization agreement with Genome Biologics for global commercialization of the latter company’s 3D Cardiac Organoid Platform.
In May 2024, InSphero became a part of the UNLOOC project, which is an initiative involving 51 stakeholders across academia and industry to advance OOC technology.
In November 2023, the company entered into a research agreement with American Type Culture Collection for oncological research through advanced 3D Cell-Based Assays.
To know more about InSphero and other organ on chip companies, access our full report.
5. SynVivo, Accelerating Real-time Study of Cell Behavior, Drug Delivery and Drug Discovery by Developing 3D Tissue and Organ-on-Chips
 |
SynVivo is a US based firm engaged in the development of proprietary microfluidic chip-based technologies and organ-on-chip models, offering a personalized approach to predict drug efficacy in patients with cancer and other diseases. The company’s novel microfluidic technology, which combines bioengineering with microfluidics, has numerous applications in life sciences, including drug delivery modeling, drug discovery, and ADME / toxicity studies. The company also provides a range of services, such as screening, assay quantification, and new model creation. In context to the screening services, the company offers target validation, compound screening, biomarkers analysis, ADME / toxicity assessments, and mechanism of action studies. Additionally, the company offers assay and model development services, focusing on creating novel 3D tissue and organ-on-chip models, endpoints, and custom chip designs tailored to specific research needs.
SynVivo offers the following Organ-on-chip technologies / models:
- SynBBB 3D Blood Brain Barrier Model
- SynRAM 3D Inflammation Model
- SynTumor 3D Cancer Model
- SynALI Lung Model
- SynTox 3D Toxicology Model
Organ-on-chips / Plates Offered:
- Linear Channel Chip
- Bifurcating Channel Chip
- Microvascular Network Chip
- Idealized Network Chips
Type of Model Offered:
- Organ / Multi-organ based
- Disease / Pathology based
Compatible Cells / Tissues / Organs / Organ Barriers:
- Lung
- Liver
- Brain
Application Area:
- Drug Discovery / Toxicology Testing
- Cancer Research
- Regenerative Medicine / Tissue Engineering
Recent Developments:
In June 2024, at the MPS World Summit 2024 in Seattle, the company representatives presented posters on “Blood-Brain-Barrier-on-Chip models for more predictive in vitro modeling of Receptor Mediated Transcytosis” and “Small airway lung-on-chip model for evaluating neutrophil-mediated damage in inflamed lung tissues”.
In April 2024, SynVivo attended the American Association for Cancer Research (AACR) Annual Meet in San Diego, where it presented a poster on “Vascularized Tumor-on-Chip Model for Evaluating Chemotherapeutic-Mediated Damage to Adjacent Healthy Tissue”.
To know more about SynVivo and other organ on chip companies, access our full report.
What About the Other Organ on Chip Companies?
The above presentation features 5 organ on chip companies selected from a pool of around 45 organ-on-chip product providers. If you are interested, you can download the Sample Report on “Organ-on-chip Market, till 2035” by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- “PhysioMimix®”
PhysioMimix® is the registered trademark of CN BIO. - “Distribution Agreement”
https://www.businesswire.com/news/home/20250108395597/en/CN-Bio-Signs-Strategic-Partnership-With-Primetech-Corporation-to-Establish-Distribution-Channel-for-OOC-Solutions-in-Japan - “Lydia Seymour”
https://cn-bio.com/cn-bio-appoints-lydia-seymour-as-vp-people-and-culture-to-further-strengthen-leadership-team/ - “SensOoChip challenge”
https://cn-bio.com/cn-bio-selected-for-nc3rs-sensoochip-challenge-to-develop-advanced-heart-on-a-chip/ - “Series B funding”
https://cn-bio.com/cn-bio-raises-21-million-investment/ - “EUROoCS Annual Meeting”
https://dynamic42.com/euroocs-annual-meeting/ - “DynamicOrgan System”
https://dynamic42.com/press-release-open-platform-for-organ-model-development/ - “Biopredic”
https://dynamic42.com/press-release-biotechs-dynamic42-and-biopredic-join-for-strategic-marketing-agreement/ - “2023 Frost and Sullivan’s Technology Innovation Leadership Award”
https://emulatebio.com/press/emulate-earns-frost-sullivans-2023-technology-innovation-leadership-award/ - “Chip-A1 Accessible Chip”
https://emulatebio.com/press/emulate-unveils-chip-a1-organ-on-a-chip-technology-applications-cancer-cosmetics/ - “Genome Biologics”
https://insphero.com/insphero-genome-biologics-truecardium-3d-cardiac-organoid-platform/ - “American Type Culture Collection”
https://insphero.com/insphero-to-revolutionize-oncology-research-through-advanced-3d-cell-based-assays-with-atcc/ - “MPS World Summit 2024”
https://www.synvivobio.com/mps-world-summit-2024-seattle/ - “American Association for Cancer Research (AACR) Annual Meet”
https://www.synvivobio.com/aacr-2024-in-san-diego-ca/